Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903649 | 0.83 | ABL1 (0.35) | — | |
| SCHEMBL6778387 | 0.83 | KDM4E (0.51) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL6773431 | 0.80 | KDM4E (0.52) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL6779787 | 0.80 | — | — | |
| SCHEMBL17485769 | 0.80 | KDM4E (0.51) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL6783680 | 0.79 | TDP1 (0.49) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL6777154 | 0.77 | KDM4E (0.51) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL6773857 | 0.77 | DHFR (0.48) | — | |
| SCHEMBL17350592 | 0.77 | KDM4E (0.65) | KDM4EALDH1A1LMNAMAPTHPGD | |
| SCHEMBL7061402 | 0.76 | MEN1 (0.41) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401829-B1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2012-08-22 | — | — | EP | claimed |
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | MICROBIOTIX, INC. | 2003-09-25 | — | — | US | claimed |
| EP-1401829-B1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1401829-A4 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX INC (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1401829-A1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | Microbiotix, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002102792-A1 | NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS | MICROBIOTIX, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181719-A1 | Novel heterocyclic antibacterial compounds | TOP1, TOP2A, TOP2B | KDM4E 2689/4885ALDH1A1 2897/4885LMNA 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.